InnoCare Pharma, k'hamphani e etelletseng pele ea biopharmaceutical, e phatlalalitse kajeno hore mokuli oa pele o fuoe teko ea bongaka ea Phase II ea Bruton's tyrosine kinase (BTK) inhibitor orelabrutinib bakeng sa kalafo ea primary immune thrombocytopenia (ITP) Chaena.
Primary immune thrombocytopenia (ITP), eo hape e bitsoang idiopathic thrombocytopenic purpura, ke lefu le fumanoeng la ho itšireletsa mafung le khetholloang ke ho fokotseha ha palo ea liplatelete tsa mali, e bakang kotsi e eketsehileng ea matetetso le ho tsoa mali[i]. Pathogenesis e kholo ea ITP ke tahlehelo ea mamello ea 'mele ho li-auto-antigens tsa platelet. Ho se mamelle hona ha 'mele ho lebisa ho senyeha ha platelet le ho fokotseha ha tlhahiso ea platelet ho tloha ho megakaryocyte ka li-autoantibodies le li-lymphocyte tsa cytotoxic T.
Ke bakuli ba ka bang 70% feela ba arabelang kalafong ea pele, bakuli ba bang ba ntse ba hana kapa ba khutlela mokhoeng ka mor'a liphekolo tse kopaneng, ka hona hoa hlokahala ho hlahloba lipheo tse ncha tsa kalafo. Thibelo ea BTK e ka fokotsa tšenyo ea liplatelete ka ho thibela tšebetso ea lisele tsa B le tlhahiso ea li-autoantibody.
Ketsahalo ea selemo le selemo ea ITP ho batho ba baholo e batla e le linyeoe tse 2-10 ho batho ba 100,000[ii],[iii]. Batho ba baholo ba ka holimo ho lilemo tse 60 ba kotsing e kholo ea ITP, 'me basali ba nang le bana ba na le kotsi e kholo ho feta banna ba sehlopha sa lilemo tse tšoanang.
Dr. Jasmine Cui, mothehi-'moho, Molula-setulo le CEO oa InnoCare o itse, "Ha ho BTK inhibitor e amohelehang bakeng sa phekolo ea bakuli ba nang le ITP lefatšeng. BTK ke kinase e ka sehloohong tseleng ea pontšo ea B cell receptor, e leng ea bohlokoa bakeng sa ts'ebetsong ea li-lymphocyte tsa B, macrophages le lisele tse ling tsa 'mele hammoho le tlhahiso ea li-antibodies ts'ebetsong ea pathological ea ITP. Orelabrutinib e na le khetho e phahameng ea sepheo le boemo ba polokeho, e lebelletsoeng ho tlisa likhetho tse ncha tsa kalafo ho bakuli ba ITP. ”
SEO U LOKELANG HO SE NKA HO SEHLOOHO ENA:
- BTK ke kinase e ka sehloohong tseleng ea pontšo ea B cell receptor, e leng ea bohlokoa bakeng sa ts'ebetsong ea li-lymphocyte tsa B, macrophages le lisele tse ling tsa 'mele oa ho itšireletsa mafung hammoho le tlhahiso ea li-antibodies ts'ebetsong ea pathological ea ITP.
- Primary immune thrombocytopenia (ITP), eo hape e bitsoang idiopathic thrombocytopenic purpura, ke lefu le fumanoeng la ho itšireletsa mafung le khetholloang ke ho fokotseha ha palo ea liplatelete tsa mali, e bakang kotsi e eketsehileng ea matetetso le ho tsoa mali[i].
- Jasmine Cui, mothehi-'moho, Molula-setulo le CEO oa InnoCare o itse, "Ha ho BTK inhibitor e amohelehang bakeng sa phekolo ea bakuli ba ITP lefatšeng.
